Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim W Harrison

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
The Journal of Allergy and Clinical Immunology|September 27, 2014
Development and validation of a novel risk score for asthma exacerbations: The risk score for exacerbationsEric D Bateman, Roland Buhl, Paul M O'Byrne, et al.
The Journal of Allergy and Clinical Immunology|February 16, 2010
Overall asthma control: the relationship between current control and future riskEric D Bateman, Helen K Reddel, Göran Eriksson, et al.
Plos One|December 30, 2020
The airways microbiome of individuals with asthma treated with high and low doses of inhaled corticosteroidsMatthew J Martin, Nur Masirah M Zain, Glenn Hearson, et al.
The Lancet. Respiratory Medicine|December 28, 2020
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trialTim W Harrison, Pascal Chanez, Francesco Menzella, et al.
Respiratory Research|April 6, 2011
Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment stepsEric D Bateman, Tim W Harrison, Santiago Quirce, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 22, 2023
Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice SubstudyRenaud Louis, Tim W Harrison, Pascal Chanez, et al.
The European Respiratory Journal|September 25, 2021
Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthmaJohn Busby, John G Matthews, Rekha Chaudhuri, et al.
The Lancet. Respiratory Medicine|September 11, 2020
Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trialLiam G Heaney, John Busby, Catherine E Hanratty, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
The Journal of Allergy and Clinical Immunology|September 27, 2014
Development and validation of a novel risk score for asthma exacerbations: The risk score for exacerbationsEric D Bateman, Roland Buhl, Paul M O'Byrne, et al.
The Journal of Allergy and Clinical Immunology|February 16, 2010
Overall asthma control: the relationship between current control and future riskEric D Bateman, Helen K Reddel, Göran Eriksson, et al.
Plos One|December 30, 2020
The airways microbiome of individuals with asthma treated with high and low doses of inhaled corticosteroidsMatthew J Martin, Nur Masirah M Zain, Glenn Hearson, et al.
The Lancet. Respiratory Medicine|December 28, 2020
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trialTim W Harrison, Pascal Chanez, Francesco Menzella, et al.
Respiratory Research|April 6, 2011
Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment stepsEric D Bateman, Tim W Harrison, Santiago Quirce, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 22, 2023
Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice SubstudyRenaud Louis, Tim W Harrison, Pascal Chanez, et al.
The European Respiratory Journal|September 25, 2021
Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthmaJohn Busby, John G Matthews, Rekha Chaudhuri, et al.
The Lancet. Respiratory Medicine|September 11, 2020
Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trialLiam G Heaney, John Busby, Catherine E Hanratty, et al.
Pageof 3